Table 1.
Infection of VGLUT3-immunoreactive neurons with PRV
|
|
PRV-infected cells/total VGLUT3-immunoreactive cells |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BAT |
Tail |
||||||||||||||
| Regions |
PRV#15 (70 hr) |
|
PRV#18 (69 hr) |
|
PRV#34 (121 hr) |
|
PRV#35 (121 hr) |
|
|||||||
| RMg and PPy | 179/236 | (76%) | 164/245 | (67%) | 220/349 | (63%) | 203/304 | (67%) | |||||||
| rRPa | 63/74 | (85%) | 56/84 | (67%) | 59/101 | (58%) | 48/75 | (64%) | |||||||
| Ventral surface of pyramidal tract | 73/106 | (69%) | 60/94 | (64%) | 183/215 | (85%) | 152/163 | (93%) | |||||||
| ROb and Giv | 25/58 | (43%) | 26/41 | (63%) | 69/101 | (68%) | 39/105 | (37%) | |||||||
| cRPa |
13/20 |
(65%) |
9/20 |
(45%) |
19/34 |
(56%) |
17/32 |
(53%) |
|||||||
PRV was inoculated into the interscapular BAT or tail, and the animals were allowed to survive for the period of time indicated. Every six 20-μm-thick frontal sections throughout the medulla oblongata were immunostained (see Fig. 4c,d) and examined for PRV immunoreactivity in VGLUT3-immunoreactive cells. Two representative cases each for inoculations into the BAT and tail are shown.